These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38171852)

  • 1. How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease.
    Fujioka H; Kataoka N; Imamura T
    Intern Med; 2024 Jan; ():. PubMed ID: 38171852
    [No Abstract]   [Full Text] [Related]  

  • 2. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
    McMurray JJV; Wheeler DC; Stefánsson BV; Jongs N; Postmus D; Correa-Rotter R; Chertow GM; Hou FF; Rossing P; Sjöström CD; Solomon SD; Toto RD; Langkilde AM; Heerspink HJL;
    JACC Heart Fail; 2021 Nov; 9(11):807-820. PubMed ID: 34446370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
    Chatur S; Vaduganathan M; Claggett BL; Mc Causland FR; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Sabatine MS; Kober L; Ponikowski P; Merkely B; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2023 Nov; 82(19):1854-1863. PubMed ID: 37634707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
    Suijk DLS; van Baar MJB; van Bommel EJM; Iqbal Z; Krebber MM; Vallon V; Touw D; Hoorn EJ; Nieuwdorp M; Kramer MMH; Joles JA; Bjornstad P; van Raalte DH
    Clin J Am Soc Nephrol; 2022 May; 17(5):663-671. PubMed ID: 35322793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
    Chen HB; Yang YL; Meng RS; Liu XW
    ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.
    Chertow GM; Correa-Rotter R; Vart P; Jongs N; McMurray JJV; Rossing P; Langkilde AM; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL;
    J Am Heart Assoc; 2023 May; 12(9):e028739. PubMed ID: 37119064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
    Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
    Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.
    Xin Y; Guo Y; Li Y; Ma Y; Li L; Jiang H
    Saudi J Biol Sci; 2019 Feb; 26(2):421-426. PubMed ID: 31485187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.
    Kalil RS; Carpenter MA; Ivanova A; Gravens-Mueller L; John AA; Weir MR; Pesavento T; Bostom AG; Pfeffer MA; Hunsicker LG
    Am J Kidney Dis; 2017 Dec; 70(6):762-769. PubMed ID: 28801121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Uric Acid with Glomerular Filtration Rate in Chronic Kidney Disease.
    Khadka M; Pantha B; Karki L
    JNMA J Nepal Med Assoc; 2018; 56(212):724-727. PubMed ID: 30387457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
    Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dapagliflozin in patients with advanced diabetic kidney disease.
    Park HS; Jung YJ; Lee DY; Moon KH; Kim B; Kim HW
    Kidney Res Clin Pract; 2018 Sep; 37(3):292-297. PubMed ID: 30254854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
    Hirai T; Kawagoe Y; Kei M; Ogawa R; Itoh T
    Biol Pharm Bull; 2020; 43(5):782-787. PubMed ID: 32378557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
    Russo E; Viazzi F; Pontremoli R; Barbagallo CM; Bombelli M; Casiglia E; Cicero AFG; Cirillo M; Cirillo P; Desideri G; D'Elia L; Ferri C; Galletti F; Gesualdo L; Giannattasio C; Iaccarino G; Leoncini G; Mallamaci F; Maloberti A; Masi S; Mengozzi A; Mazza A; Muiesan ML; Nazzaro P; Palatini P; Parati G; Rattazzi M; Rivasi G; Salvetti M; Tikhonoff V; Tocci G; Ungar A; Verdecchia P; Virdis A; Volpe M; Grassi G; Borghi C;
    J Nephrol; 2022 Jan; 35(1):211-221. PubMed ID: 33755930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Intern Med; 2021; 60(15):2367-2374. PubMed ID: 34334588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.
    Butt JH; Docherty KF; Claggett BL; Desai AS; Petersson M; Langkilde AM; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Køber L; Lam CSP; Martinez FA; Ponikowski P; Sabatine MS; Shah SJ; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV
    JAMA Cardiol; 2023 Apr; 8(4):386-393. PubMed ID: 36811901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus.
    Ahmadieh H; Azar S
    Diabetes Technol Ther; 2017 Sep; 19(9):507-512. PubMed ID: 28749169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.